Market Snapshot

S&P Futures
4,141.75
Dow Futures
33,071.00
NASDAQ Futures
14,017.75

9.45$-0.25 -2.58%
At close    04:00 PM   
From: To:

Stock Snapshot

10.08
Prev. Close
9.51
Open
286.24M
Market Cap
1.36M
Number of Shares
9.10
Day Low
9.59
Day High
9.45
-
P/E Ratio
14.99M
Free Float in %
-1.85
EPS 2021
4.70
Book Value per Share
4.22
Cash Flow per Share
HOOKIPA Pharma Inc. (HOOK)
HOOKIPA Pharma Inc. (HOOK) stock rallied over -2.58% intraday to trade at $9.45 per share on NASDAQ. The stock opened with a fall of -5.65% at $9.51 and touched an intraday high of $9.59, declining 4.86% against the last close of $10.08. The stock went to a low of $9.10 during the session.

Historical Prices

DateOpenCloseAdj. CloseDaily HighDaily LowVolume
2021-06-18$9.51$9.45$9.45$9.59$9.10883,300
2021-06-17$9.50$9.70$9.70$9.79$9.35456,900
2021-06-16$9.50$9.58$9.58$9.70$9.31590,800
2021-06-15$9.86$9.60$9.60$9.92$9.40501,200
2021-06-14$9.87$9.88$9.88$10.03$9.52868,900
2021-06-11$10.09$9.89$9.89$10.09$9.62810,500
2021-06-10$10.28$10.05$10.05$10.36$9.81982,100
2021-06-09$11.02$10.08$10.08$11.15$10.012,208,600
2021-06-08$13.40$10.70$10.70$13.40$10.263,877,200
2021-06-07$17.00$13.25$13.25$18.33$12.751,141,200
2021-06-04$16.39$16.86$16.86$17.10$15.80255,800
HOOKIPA Pharma Inc.
350 Fifth Avenue
72nd Floor Suite 7240
New York, NY 10118
United States

http://www.hookipapharma.com
431 890 6360
Employees
109
Sector
Healthcare
Sales or Revenue
Industry
Biotechnology
5Y Sales Change
-
Fiscal Year Ends
2020-12-30
Mr. Joern Aldag
CEO & Director
Dr. Reinhard Kandera
CFO & Director
Dr. Igor Matushansky M.D., Ph.D.
Chief Medical Officer and Global Head of R&D
HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.